Unlock the Editor’s Digest at no cost
Roula Khalaf, Editor of the FT, selects her favorite tales on this weekly publication.
Novo Nordisk has stated a trial for its once-a-week weight loss injection has fallen wanting its goal, sending the Danish drugmaker’s shares 10 per cent decrease on Monday.
The 84-week trial discovered that Novo’s CagriSema achieved a weight loss of 23 per cent in contrast with 25.5 per cent with tirzepatide, which is utilized in therapies made by rival Eli Lilly.
Novo has endured a difficult 12 months marked by a sliding share worth, a board exodus and threats of cheaper copycat variations of its Wegovy remedy coming to market.
Earlier this month, the corporate — as soon as Europe’s largest by market capitalisation — introduced that it anticipated web gross sales to fall by as a lot as 13 per cent this 12 months, a deeper hit than analysts had anticipated.
Novo’s shares have virtually halved over the previous 12 months and commerce two-thirds beneath their peak of June 2024.
This is a growing story
